Skip to main content
08/09/2025

VHIR takes part in the GIMM Festival 2025 in Lisbon with activities on ageing and longevity

Taula rodona al GIMM Festival

Taula rodona al GIMM Festival

GIMM Festival

GIMM Festival

Taller d'hidrogels al GIMM Festival

Taller d'hidrogels al GIMM Festival

Pòster al GIMM Festival

Pòster al GIMM Festival

08/09/2025

The annual event offered a space for dialogue between the scientific community and society on how to address the future of ageing through research and innovation.

The Vall d’Hebron Research Institute (VHIR) took part in the GIMM Festival 2025, held from 4 to 6 September at the Pavilhão de Portugal in Lisbon.
The event, organised annually by the Gulbenkian Institute for Molecular Medicine (GIMM), aims to build a bridge between science and society, offering a space for dialogue, discovery and engagement with global challenges.

Each year, the festival addresses a different theme. This edition focused on ageing and longevity, encouraging both the scientific community and the general public to reflect on how we can face the future of ageing through research and innovation. The scientific sessions took place on 4 and 5 September in English, while on 6 September the festival opened to the public in Portuguese, with outreach and participatory activities.

On this occasion, VHIR played an active role with several contributions:

  • A round table on the questions biomedical sciences should consider regarding the social aspects of ageing.
  • A hands-on workshop on hydrogels and the role of future materials in promoting healthy ageing.
  • A stand on speech therapy with resources for voice re-education in older adults.
  • The presentation of scientific posters.

The GIMM Festival is part of the European project GIMM CARE (Teaming for Excellence – Boosting Clinical Research for the Benefit of Society), which fosters excellence in clinical research to contribute to society’s well-being.

Related news

Docetaxel, carried by Soluplus, proved to be the most effective and least toxic combination to cross the blood-brain barrier and attack the tumour directly.

Based on the study led by VHIR, a clinical trial has been approved for patients with locally advanced pancreatic cancer.

Vall d'Hebron participates in a project to develop innovative microsampling technology, making blood collection more accessible and patient-centered.

Related professionals

Fernanda Raquel Da Silva Andrade

Fernanda Raquel Da Silva Andrade

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Diana Fernandes de Rafael

Diana Fernandes de Rafael

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Albert Blanco Grau

Albert Blanco Grau

Predoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Daniel Bravo Nieto

Daniel Bravo Nieto

Predoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.